Related Experiment Videos
Continuous arteriovenous haemofiltration. A new kidney replacement therapy
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association
|January 1, 1981
Summary
Continuous arteriovenous hemofiltration (CAVH) effectively treated acute renal failure in intensive care patients. This method allowed fluid balance and improved survival rates, offering a viable alternative to traditional dialysis.
Area of Science:
- Nephrology
- Intensive Care Medicine
- Renal Replacement Therapy
Background:
- Acute oliguric renal failure is a serious complication in intensive care settings.
- Continuous arteriovenous hemofiltration (CAVH) is an emerging renal replacement therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of CAVH as a sole treatment for acute oliguric renal failure in intensive care patients.
- To assess the impact of CAVH on fluid and electrolyte balance, and patient survival.
Main Methods:
- Twenty intensive care patients with acute oliguric renal failure were treated exclusively with CAVH.
- Fluid substitution used K+-free Ringer's lactate solution.
- Extracorporeal anticoagulation was achieved with low-dose continuous heparin (10 IU/kg/hr).
Main Results:
- The mean spontaneous filtration rate was 8.8 +/- 3.5 ml/min.
- Steady-state plasma creatinine levels reached 6.4 +/- 3.5 mg/dl.
- Eight out of twenty patients recovered kidney function and survived.
Conclusions:
- CAVH provides optimal control of water and electrolyte balance.
- Continuous fluid withdrawal via CAVH is well-tolerated and allows unlimited parenteral nutrition.
- CAVH is a safe and effective treatment option for acute renal failure in the ICU, with no specialized personnel or equipment investment required.